Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Successfully Enrolls Targeted Number of Patients in Phase 3 Study of Prolastin®-C for Emphysema Due to Alpha-1-Antitrypsin Deficiency Grifols, a global leader in plasma-derived medicines, has achieved its enrollment goal of 339 patients for the SPARTA clinical trial. This groundbreaking study aims to assess the effectiveness and safety of two different weekly doses of Grifols' Prolastin®..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 14.
  • textsms

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampli

AIM ImmunoTech Inc. (NYSE American: AIM) has commenced its Phase 2 study to evaluate the potential therapeutic effects of Ampligen® on individuals with post-COVID conditions. The enrollment and dosing of the first subject have already taken place, with encouraging preliminary data on Ampligen. The study is projected to be fully enrolled by Q4 2023. In order to facilitate this study, AIM has esta..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 11.
  • textsms